The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Surveillance for melanoma (MEL): Results of a database study of stage I-III MEL.
 
Corey Rearick
No Relationships to Disclose
 
Fei Ding
No Relationships to Disclose
 
Yan Lin
No Relationships to Disclose
 
Amy Rose
No Relationships to Disclose
 
Cindy Sander
No Relationships to Disclose
 
Michael Davis
No Relationships to Disclose
 
Panayiotis V Benos
No Relationships to Disclose
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Incyte; Merck; Newlink Genetics; Novartis; OncoSec
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst)
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche
Research Funding - Merck (Inst); Prometheus (Inst)
 
Diwakar Davar
Consulting or Advisory Role - Incyte; Merck
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Incyte; Merck